Get the Stockscreener App
1.63
2.11%
-0.03
Silo Pharma Inc stock is traded at $1.63, with a volume of 62,889.
It is down -2.11% in the last 24 hours and up +49.08% over the past month.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
See More
Previous Close:
$1.66
Open:
$1.68
24h Volume:
62,889
Relative Volume:
0.02
Market Cap:
$7.38M
Revenue:
$72,100
Net Income/Loss:
$-3.60M
P/E Ratio:
-1.3697
EPS:
-1.19
Net Cash Flow:
$-3.37M
1W Performance:
+0.93%
1M Performance:
+49.08%
6M Performance:
+37.71%
1Y Performance:
+8.34%
1-Day Range:
$1.60
$1.68
1-Week Range:
$1.56
$1.86
52-Week Range:
$0.77
$4.50
Silo Pharma Inc Stock (SILO) Company Profile
Name
Silo Pharma Inc
Sector
Industry
Phone
(718) 400-9031
Address
677 N. WASHINGTON BLVD, SARASOTA
Compare SILO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SILO
SILO PHARMA INC
|
1.71 | 17.96M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1978 | 409.20M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
GOODO
Gladstone Commercial Corporation
|
20.70 | 372.90M | 0 | 0 | 0 | 0.00 |
|
MOBBW
Mobilicom Limited Warrants
|
0.4356 | 278.60M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.26 | 96.03M | 0 | 0 | 0 | 0.00 |
|
JUNE
Dhandho Junoon Etf
|
4.00 | 52.42M | 0 | 0 | 0 | 0.00 |
Silo Pharma Inc Stock (SILO) Latest News
Monitoring SILO Pharma Inc (SILO) after recent insider movements - Knox Daily
SILO Pharma Inc (SILO) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
SILO Pharma Inc’s Market Journey: Closing Strong at 1.79, Up 11.18 - The Dwinnex
Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment - GlobeNewswire
Silo Pharma files provisional patent for PTSD treatment - Investing.com India
Silo Pharma Files Breakthrough PTSD Treatment Patent, Expands Columbia Tech Portfolio - StockTitan
Looking For A Good Stock? Let This SILO Pharma Inc (NASDAQ: SILO) Analysis Help. - Stocks Register
After A Patent Win, Analysts Think This Penny Stock Can Gain 465% In 2025 - Barchart
Silo Pharma awarded U.S. patent for PTSD treatment - Yahoo Finance
Silo Pharma secures patent for PTSD intranasal treatment By Investing.com - Investing.com Nigeria
SILO Pharma flies high on impending patent for intranasal PTSD drug - Mugglehead
Crude Oil Down 1%; US Weekly Jobless Claims Decline - Benzinga
Silo Pharma shares soar on patent allowance news By Investing.com - Investing.com South Africa
Silo Pharma shares soar on patent allowance news - Investing.com India
Silo Pharma secures patent for PTSD intranasal treatment - Investing.com
Silo Pharma Awarded US Patent for Groundbreaking PTSD Treatment and Prepares for SPC-15 Clinical Trial - The Manila Times
Silo Pharma Secures Key Patent Protection for PTSD Treatment SPC-15, Strengthens IP Portfolio - StockTitan
US Stocks Down; Acuity Brands Posts Weak Revenue - Benzinga
Silo Pharma progresses with PTSD and pain treatments - Investing.com
Silo Pharma Issues Letter to Shareholders Detailing - GlobeNewswire
Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain - Yahoo Finance UK
Silo Pharma initiates pharmacokinetic, tolerability study for SP-26 - Yahoo Finance
Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia - The Manila Times
Silo Pharma Initiates Pharmacokinetic and Tolerability Study for Sp-26 Targeting Chronic Pain and Fibromyalgia - Marketscreener.com
Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain - The Bakersfield Californian
Silo Pharma partners with Kymanox to develop ketamine implant - MSN
Why Is Silo Pharma Stock Gaining Today? - Benzinga
Silo Pharma advances ketamine implant for chronic pain By Investing.com - Investing.com UK
Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management - GlobeNewswire
Silo Pharma Partners with Kymanox to Develop Novel Ketamine Implant Device | SILO Stock News - StockTitan
Silo Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Silo Pharma stock hits 52-week low at $0.83 amid market challenges - Investing.com Canada
Silo Pharma stock hits 52-week low at $0.83 amid market challenges By Investing.com - Investing.com South Africa
Silo Pharma CEO Eric Weisblum buys $4,625 in company stock - Investing.com
Silo Pharma CEO Eric Weisblum buys $4,625 in company stock By Investing.com - Investing.com Canada
Silo Pharma Inc. Share PriceSILO, RNS News, Articles, Quotes, & Charts (NASDAQ: SILO) - Proactive Investors Australia
Silo Pharma reports promising preclinical results in treating severe stress-related disorders - Proactive Investors UK
Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders - The Manila Times
Silo Pharma reports progress in PTSD treatment study - Investing.com
Silo Pharma reports progress in PTSD treatment study By Investing.com - Investing.com UK
Silo Pharma Third Quarter 2024 Earnings: US$0.22 loss per share (vs US$0.21 loss in 3Q 2023) - Yahoo Finance
SILOSilo Pharma, Inc. Latest Stock News & Market Updates - StockTitan
Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant - GlobeNewswire
Silo Pharma Inc Stock (SILO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Silo Pharma Inc Stock (SILO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Weisblum Eric | CEO and President |
Nov 20 '24 |
Buy |
0.95 |
2,500 |
2,375 |
182,932 |
| Weisblum Eric | CEO and President |
Nov 22 '24 |
Buy |
0.90 |
2,500 |
2,250 |
185,432 |
| Weisblum Eric | CEO and President |
Jun 12 '24 |
Buy |
1.11 |
4,438 |
4,926 |
180,432 |
| Weisblum Eric | CEO and President |
Jun 11 '24 |
Buy |
1.08 |
562 |
607 |
175,994 |
| Weisblum Eric | CEO and President |
Apr 04 '24 |
Buy |
1.96 |
600 |
1,176 |
175,032 |
| Weisblum Eric | CEO and President |
Apr 05 '24 |
Buy |
2.03 |
400 |
812 |
175,432 |
| Weisblum Eric | CEO and President |
Mar 28 '24 |
Buy |
1.94 |
3,408 |
6,612 |
173,332 |
| Weisblum Eric | CEO and President |
Apr 01 '24 |
Buy |
1.91 |
1,100 |
2,101 |
174,432 |
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):